Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • Adverse Reactions:...

    Adverse Reactions: Cefotaxime, Oflaxicin, Cefixime told to carry Warning by CDSCO

    Meghna A SinghaniaWritten by Meghna A Singhania Published On 2019-04-17T12:26:26+05:30  |  Updated On 16 Aug 2021 4:43 PM IST

    New Delhi: The national regulatory body for Indian Pharmaceutical and Medical Device, Central Drugs Standard Control Organisation (CDSCO) has ordered all drugmakers manufacturing commonly used antibiotics to place safety warning on these medicines and ensure that this information is made available to the general public.


    These commonly used antibiotics include Cefotaxime, Ofloxacin, Cefixime, Tranexamic Acid, Quetiapine, Sulfasalazine and Sodium Valproate.


    The move comes in following a caution raised by the National Co-ordination Centre of the Pharmacovigilance Programme of India (PvPI), on adverse reactions that were being reported from some commonly-used antibiotics.


    An antibiotic is a type of antimicrobial substance active against bacteria and is the most important type of antibacterial agent for fighting bacterial infections.


    However, PvPI reported that people using common antibiotic Ofloxacin are more exposed to the risk of developing Stevens-Johnson Syndrome, a rare and fatal disorder of the skin and another potentially life-threatening dermatologic disorder called toxic epidermal necrolysis. While injectable cefotaxime, another common antibiotic used for bacterial infections, especially joint infections, pneumonia and urinary tract infections, has come under the scanner for causing angioedema, an allergic reaction that leads to rapid oedema or swelling in patients.


    In stringent view of the matter, the PvPI recommended CDSCO to take necessary steps to incorporate the adverse drug reactions in the prescribing leaflet of these drugs marketed in the country.


    PvPI's suggestions were put forth before the subject expert committee under the Drug Controller General India (DCGI) and after an elaborate examination of the same, it was concluded to incorporate safety cautions in its packages of all such antibiotics.


    In mindfulness of the matter, Dr S Eswara Reddy, the DCGI, recently wrote to drug controllers in all States and Union Territories stating the same.


    "All zonal and sub-zonal officers have been instructed to direct the manufacturers of these formulations to mention the additional reaction in the package insert or promotional literature of the drug," notes the letter sent the State Drug Controllers.


    Speaking about the decision, Eswara Reddy, the Drug Controller General of India and head of the CDSCO told The Hindu, "We were alerted to this adverse reaction last year and, after talks with the Ministry and the PvPI, the decision was taken to write to all State authorities to ask manufacturers to include this information on the packaging itself. The idea is to ensure that doctors and users are aware of the adverse reactions.


    Backing the move, Dr Rommel Tickko, associate director, Max Super Specialty Hospital Saket, told TOI that the new notifications were significant. "We will now have to be extra careful about skin reactions in people who are prescribed these medicines," he added.





    Also Read: Sale of antibiotics, prescription drugs OTC; Court asks Government to reply

    angioedemaantibioticsbacterial infectionCDSCOcefiximeCefotaximeCentral Drugs Standard Control Organisationcommon antibioticsDCGIdermatdermatologicdermatologisthealth careinfectioninjectableJohnson SyndromemedicalmedicinesOfloxacinphama newspharmapharma news indiaPharmacovigilance Programme of IndiaPVpiquetiapinesafety warningside effectsskin diseaseSodium Valproate.SulfasalazineTranexamic Acid
    Source : with inputs

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Meghna A Singhania
    Meghna A Singhania

      Meghna A Singhania is the founder and Editor-in-Chief at Medical Dialogues. An Economics graduate from Delhi University and a post graduate from London School of Economics and Political Science, her key research interest lies in health economics, and policy making in health and medical sector in the country. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok